Biogen Acquires Alcyone Therapeutics

Vertex Pharmaceuticals Acquires ViaCyte for $320M

July 11, 2022

Biotechnology

Vertex Pharmaceuticals agreed to acquire clinical-stage cell therapy company ViaCyte for $320 million in cash. The deal gives Vertex additional stem cell lines, IP and GMP manufacturing capabilities intended to accelerate its VX-880 and other cell replacement therapy programs for type 1 diabetes.

AbCellera Acquires TetraGenetics

September 13, 2021

Biotechnology

AbCellera Biologics Inc. acquired TetraGenetics, Inc. in an all-cash transaction to integrate TetraGenetics' recombinant transmembrane protein expression platform into AbCellera's antibody discovery technology stack. The acquisition expands AbCellera's ability to generate antibodies against difficult-to-drug ion channels, GPCRs and other transmembrane targets, and includes upfront and milestone-based payments.

Harmony Biosciences Acquires Epygenix Therapeutics

April 30, 2024

Biotechnology

Harmony Biosciences has acquired Epygenix Therapeutics, adding a late-stage rare epilepsy franchise (including EPX-100 and EPX-200) to its CNS pipeline. Harmony paid $35 million in cash with up to $130 million in development/regulatory milestones and up to $515 million in potential sales milestones to complete the transaction.

BioVie Acquires Biopharma Assets of NeurMedix

June 11, 2021

Pharmaceuticals

BioVie Inc. acquired the biopharmaceutical assets of privately held NeurMedix, including NE3107, an orally administered small-molecule inhibitor targeting neuroinflammation and insulin resistance. The deal paid NeurMedix shareholders newly issued BioVie shares and cash at closing, with additional contingent cash and equity payments tied to clinical and regulatory milestones; the acquisition expands BioVie's pipeline into neurodegenerative diseases and oncology.

Boehringer Ingelheim Acquires Nerio Therapeutics

August 6, 2024

Biotechnology

Boehringer Ingelheim agreed to acquire Nerio Therapeutics, a San Diego-based preclinical biotech focused on PTPN2/N1 phosphatase inhibitors for immuno-oncology, for up to $1.3 billion. Nerio was invested/incubated by Viva BioInnovator and backed by a syndicate including Avalon Ventures; the deal is intended to accelerate development of Nerio’s preclinical program as a cornerstone of Boehringer’s immuno-oncology portfolio.

Biogen Acquires Reata Pharmaceuticals

July 28, 2023

Biotechnology

Biogen Inc. agreed to acquire Reata Pharmaceuticals, Inc. for $172.50 per share in cash, representing an enterprise value of approximately $7.3 billion. The acquisition adds Reata's FDA-approved SKYCLARYS (omaveloxolone) for Friedreich's ataxia to Biogen's rare disease portfolio and is expected to be significantly accretive to Biogen's Non-GAAP diluted EPS beginning in 2025; the transaction was anticipated to close in Q4 2023.